MyChesCo on MSN4h
Johnson & Johnson’s TREMFYA Demonstrates Significant Benefits in Psoriatic Arthritis StudyHOUSE, PA — Johnson & Johnson has announced promising results from its Phase 3b APEX trial for TREMFYA® (guselkumab), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback